James Fadiman: The Father of the Modern Microdosing Protocol
Dr. James Fadiman is the researcher most responsible for the modern microdosing protocol. Here is who he is, what his research has actually documented, and where the protocol came from.
In one sentence: Dr. James Fadiman is the researcher who formalized the modern microdosing protocol — one day on, two days off — and who has been quietly collecting microdosing reports from volunteers for over a decade.
If you have read anything about microdosing in the past ten years, James Fadiman’s name has probably been in the room even if it was not on the page. The protocol most beginners use, the language most communities adopt, and the framework most researchers reference all trace back to his work. He is the closest thing the field has to a founding figure.
This page covers who Fadiman is, what he has actually published, where the protocol came from, and the limitations of the research as it currently stands.
Who is James Fadiman?
James Fadiman, born 1939, is an American psychologist with a doctorate in psychology from Stanford. He has spent most of his professional life at the intersection of psychology, transpersonal research, and consciousness studies. He helped found the Institute of Transpersonal Psychology in 1975 and taught there for decades.
His connection to psychedelics is older than most of the modern field. In the early 1960s, Fadiman worked with Willis Harman at the International Foundation for Advanced Study in Menlo Park, California. The IFAS was a small research group studying the effects of psychedelics — primarily LSD and mescaline — on creativity, problem-solving, and therapeutic process. The work was legal at the time and was funded by private donors. Fadiman participated in some of the first formal studies of psychedelics as tools for enhanced cognition rather than as treatments for mental illness.
In 1965, the team published a paper called “Psychedelic Agents in Creative Problem-Solving: A Pilot Study” in the journal Psychological Reports. The study gave 27 male engineers, scientists, and architects a moderate dose of mescaline and asked them to work on technical problems they had been stuck on. The results were striking — most participants reported breakthroughs on problems they had been wrestling with for weeks. Several of the breakthroughs went on to become patented inventions and published research.
The 1965 study was one of the last formal psychedelic research projects in the United States before the Controlled Substances Act of 1970 effectively shut the field down for the next thirty years.
Where did the Fadiman Protocol come from?
The protocol most people now associate with Fadiman’s name — one day on, two days off — emerged out of his ongoing curiosity about whether sub-perceptual doses of psychedelics could produce the cognitive and mood benefits of full doses without the disruptive nature of the trip itself.
In 2010, Fadiman published The Psychedelic Explorer’s Guide, which included a chapter on what he called “sub-perceptual” dosing. The book described the rationale for very low doses — roughly one-tenth of a recreational dose — and proposed a basic schedule of dosing every third day. The schedule was based on a few practical observations:
- Tolerance to psilocin builds quickly. Daily dosing produces diminishing returns within a week.
- A 48-hour gap between doses appeared, in his volunteer reports, to be enough to reset the response.
- The off-days created space for integration and noticing what shifted, which Fadiman considered essential to the practice.
The schedule was not derived from a formal pharmacokinetic model. It was an empirical guess that turned out to align with what later receptor-binding research would suggest. Tolerance to 5-HT2A activation does in fact reset within roughly two days at low doses, which is consistent with the protocol’s spacing.
What does Fadiman’s research actually consist of?
This is the part that needs honest framing. Fadiman’s microdosing research is unusual because most of it has been done outside the formal academic publication system. There are several reasons for this.
The legal situation. Psilocybin remains a Schedule I controlled substance in the United States. Conducting formal research on it requires DEA approvals, IRB oversight, and institutional support that has been historically difficult to obtain. Fadiman’s microdosing work was largely done as an independent researcher collecting voluntary reports from people who were already microdosing on their own.
The methodology. Fadiman’s approach has been to gather large numbers of self-reports from microdosing volunteers via a website and to look for patterns. The dataset, by his own description, includes thousands of people from many countries. He has presented findings at conferences (notably MAPS Psychedelic Science in 2017) and discussed them in interviews and lectures, but the data has not been published in a traditional peer-reviewed journal in its entirety.
The findings. Across the volunteer reports Fadiman has collected, the most commonly reported benefits include improved mood, increased focus, reduced anxiety, better sleep, and more positive social interactions. The most commonly reported difficulties include physical discomfort at higher microdoses, increased anxiety in some users, and inconsistent effects.
These reports are valuable but they are not controlled studies. They cannot rule out placebo effects, expectation effects, or selection bias. Fadiman has been clear about this himself in his public talks. His position is that the volunteer data is a starting point for hypothesis generation, not proof of clinical efficacy.
What does formal microdosing research show?
Since around 2018, more rigorous studies have begun to appear, mostly from research groups in the Netherlands, the UK, and Australia. The picture they paint is more complicated than the volunteer reports.
A 2021 placebo-controlled study by Szigeti and colleagues at Imperial College London found that microdosers and placebo-takers reported similar improvements on most measures, suggesting a strong expectation effect. A 2022 study by Polito and Stevenson at Macquarie University found small but real cognitive improvements in microdosers compared to controls, though the effects were modest. A 2023 imaging study from the University of Zurich found measurable but subtle changes in brain network activity at low doses.
The current honest summary: microdosing produces real effects in some people, the effects are smaller than enthusiasts often claim, the placebo contribution is significant, and the protocol Fadiman proposed is a reasonable starting point for personal experimentation but should not be confused with clinical treatment.
Why does the protocol still matter?
Even if the formal research is mixed, Fadiman’s contribution to the field is real and worth understanding.
He gave the practice a vocabulary. Before 2010, “microdosing” was not a common term. The phrase, the schedule, the framing of integration days, and the basic do’s and don’ts all come from his work. The community language exists because he created it.
He took the practice seriously when no one else would. For most of the 2000s, microdosing was not a respectable topic. Fadiman approached it as a researcher rather than a drug enthusiast and treated the volunteers as collaborators rather than subjects. This framing gave the modern field its scientific posture even before the science caught up.
He documented thousands of cases. The volunteer database, whatever its statistical limitations, is the largest collection of microdosing experience reports in existence. It is a starting point for any researcher who wants to know what people actually report when they do this.
What we still do not know
- The full results of Fadiman’s volunteer database have not been published in a peer-reviewed journal. The dataset is a resource the field would benefit from analyzing more formally.
- Whether the Fadiman protocol’s 1-on-2-off schedule is genuinely optimal or whether other schedules (such as the Stamets stack’s 4-on-3-off rhythm) produce different outcomes for different goals.
- How much of the reported microdosing benefit is pharmacological and how much is the framing, ritual, and self-attention the practice produces.
Frequently Asked Questions
Who is James Fadiman?
James Fadiman is an American psychologist with a doctorate from Stanford. He worked on early psychedelic research with Willis Harman at the International Foundation for Advanced Study in the 1960s and is the researcher most responsible for the modern microdosing protocol.
What is the Fadiman protocol?
The Fadiman protocol is a microdosing schedule of one day on, two days off, repeated for 4-8 weeks before taking a break. The dose is sub-perceptual — typically 0.1 to 0.2 grams of dried psilocybin mushrooms.
Has Fadiman published peer-reviewed research on microdosing?
Fadiman has published widely on psychedelic research more generally, including the landmark 1965 creative problem-solving study. His specific microdosing work has been presented at conferences and discussed in interviews and books, but the full volunteer dataset has not been published in a traditional peer-reviewed journal.
Is microdosing actually effective according to research?
The picture is mixed. Formal placebo-controlled studies suggest microdosing produces real but modest cognitive and mood effects, with significant placebo contribution. The protocol Fadiman proposed is reasonable as a starting point for personal experimentation but is not yet supported by clinical trials sufficient to call it a treatment.
How old is James Fadiman?
Fadiman was born in 1939 and is in his 80s as of 2026. He continues to give lectures and interviews about his research.
Sources and Further Reading
- Fadiman, J. (2011). The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys. Park Street Press.
- Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. (1966). “Psychedelic agents in creative problem-solving: a pilot study.” Psychological Reports, 19(1), 211–227.
- Fadiman, J., & Korb, S. (2019). “Might microdosing psychedelics be safe and beneficial? An initial exploration.” Journal of Psychoactive Drugs, 51(2), 118–122.
- Szigeti, B., et al. (2021). “Self-blinding citizen science to explore psychedelic microdosing.” eLife, 10, e62878.
- Polito, V., & Stevenson, R. J. (2019). “A systematic study of microdosing psychedelics.” PLOS ONE, 14(2), e0211023. MAPS Bulletin coverage
Related on The Microdose Movement
- Microdosing Mushrooms for Anxiety and Depression — uses the Fadiman protocol as the beginner-friendly default
- Psilocybin and Neuroplasticity — the research that may explain why microdoses work even when subtle
- The Default Mode Network — the brain system Fadiman’s protocol modulates
This page is for educational purposes. Nothing here is medical advice. The Microdose Movement is an educational community, not a clinical provider.